Chief Executive Officer,
Chief Financial Officer
Mr. Shallcross was appointed as the Company’s CEO on December 6, 2018 and has served as the Company’s CFO since joining the Company in June 2015
Mr. Shallcross brings to the Company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies
Mr. Shallcross served as EVP and CFO of Nuo Therapeutics, Inc., Acting CFO of Senseonics, and CFO and Treasurer of Vanda Pharmaceuticals, Inc.